Autolus Q3 2024 Earnings Report
Key Takeaways
Autolus Therapeutics reported a net loss of $82.1 million for the third quarter ended September 30, 2024. The FDA approved AUCATZYL, triggering a $30 million milestone payment from Blackstone. The company's cash and cash equivalents totaled $657.1 million.
AUCATZYL (obecabtagene autoleucel) was approved by the US FDA on November 8, 2024.
BLA approval triggered a $30 million milestone payment to Autolus from Blackstone.
Matthias Will M.D. was appointed as Chief Development Officer, effective September 30, 2024.
Obe-cel is under regulatory review in both the EU and the UK.
Autolus
Autolus
Forward Guidance
Autolus anticipates several milestones in the near term. Obe-cel FELIX data will be presented at the American Society of Hematology (ASH) meeting in December 2024. Initial data from the SLE Phase 1 study is expected in Q1 2025 and initial data from the PY01 trial of obe-cel in pediatric ALL is expected in H2 2025.
Positive Outlook
- Obe-cel FELIX data at American Society of Hematology (ASH) meeting December 2024
- Obe-cel in autoimmune disease – initial data from SLE Phase 1 study Q1 2025
- Initial data from PY01 trial of obe-cel in pediatric ALL H2 2025
- SLE Phase 1 trial presentation at medical conference H2 2025